Novel mechanisms for estrogen-induced neuroprotection
- PMID: 16636299
- DOI: 10.1177/153537020623100505
Novel mechanisms for estrogen-induced neuroprotection
Abstract
Estrogens are gonadal steroid hormones that are present in the circulation of both males and females and that can no longer be considered within the strict confines of reproductive function. In fact, the bone, the cardiovascular system, and extrahypothalamic regions of the brain are now well-established targets of estrogens. Among the numerous aspects of brain function regulated by estrogens are their effects on mood, cognitive function, and neuronal viability. Here, we review the supporting evidence for estrogens as neuroprotective agents and summarize the various mechanisms that may be involved in this effect, focusing particularly on the mitochondria as an important target. On the basis of this evidence, we discuss the clinical applicability of estrogens in treating various age-related disorders, including Alzheimer disease and stroke, and identify the caveats that must be considered.
Similar articles
-
Effects of estrogen in the brain: is it a neuroprotective agent in Alzheimer's disease?Curr Aging Sci. 2010 Jul;3(2):113-26. doi: 10.2174/1874609811003020113. Curr Aging Sci. 2010. PMID: 20167003 Review.
-
Non-feminizing estrogens: a novel neuroprotective therapy.Mol Cell Endocrinol. 2014 May 25;389(1-2):40-7. doi: 10.1016/j.mce.2013.12.017. Epub 2014 Jan 11. Mol Cell Endocrinol. 2014. PMID: 24424441 Free PMC article. Review.
-
Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone.J Neurotrauma. 2000 May;17(5):367-88. doi: 10.1089/neu.2000.17.367. J Neurotrauma. 2000. PMID: 10833057 Review.
-
[Mechanisms of neuroprotective effect of estrogens associated with vascular endothelial growth factor expression].Izv Akad Nauk Ser Biol. 2007 Mar-Apr;(2):145-56. Izv Akad Nauk Ser Biol. 2007. PMID: 17665642 Review. Russian.
-
Progestins and neuroprotection: are all progestins created equal?Minerva Endocrinol. 2007 Jun;32(2):95-102. Minerva Endocrinol. 2007. PMID: 17557035 Review.
Cited by
-
Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing.Front Pharmacol. 2018 Apr 27;9:422. doi: 10.3389/fphar.2018.00422. eCollection 2018. Front Pharmacol. 2018. PMID: 29755356 Free PMC article. Review.
-
Risk of Parkinson's disease after tamoxifen treatment.BMC Neurol. 2010 Apr 12;10:23. doi: 10.1186/1471-2377-10-23. BMC Neurol. 2010. PMID: 20385012 Free PMC article.
-
Sexual Dimorphism in Lesion Size and Sensorimotor Responses Following Spinal Cord Injury.Front Neurol. 2022 Jul 19;13:925797. doi: 10.3389/fneur.2022.925797. eCollection 2022. Front Neurol. 2022. PMID: 36994113 Free PMC article.
-
Age- and Sex-Specific Prevalence and Modifiable Risk Factors of Mild Cognitive Impairment Among Older Adults in China: A Population-Based Observational Study.Front Aging Neurosci. 2020 Oct 30;12:578742. doi: 10.3389/fnagi.2020.578742. eCollection 2020. Front Aging Neurosci. 2020. PMID: 33192471 Free PMC article.
-
Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms.Curr Neuropharmacol. 2018;16(4):484-504. doi: 10.2174/1570159X15666170828165711. Curr Neuropharmacol. 2018. PMID: 28847295 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources